Warning: Use of undefined constant custom_pagination - assumed 'custom_pagination' (this will throw an Error in a future version of PHP) in /home/customer/www/inmunotek.com/public_html/wp-content/themes/enfold/functions.php on line 1022


MV130 prevents respiratory infections in CVID patients

MV130 (Bactek)July 2020

MV130 (Bactek) prevents recurrent respiratory infections in patients with common variable immunodeficiency (CVID) according to a pilot study published in Biomedicines. The study is a proof of concept to evaluate MV130 as a trained immunity-based vaccine (TIbV) in CVID patients with recurrent respiratory infections despite prophylactic treatment with replacement immunoglobulins and antibiotics.
More info

INMUNOTEK´s research in Allergy Virtual Issue

March 2020

The research study on the effect of aluminum in the new allergoid-mannan conjugates carried out at the Complutense University of Madrid and INMUNOTEK published in Allergy, has been selected to be included in the opening issue of the Virtual Issue collection, aimed to promote the dissemination of outstanding studies.
More info

Financial Times features INMUNOTEK

Financial TimesDecember 2019

Financial Times features INMUNOTEK as an example of a Spanish company with strong growth along the years even in unfavorable situations. According to the economic newspaper, the strength of these companies is based on their commitment to innovation and competitiveness. This allows to focus its productive activity towards foreign markets, have a sustained growth and create employment.
More info

National Innovation Award to INMUNOTEK

logo PNID2November 2019

The Spanish Ministry of Science, Innovation and Universities has awarded INMUNOTEK the National Innovation Award 2019. This price, the highest award granted in Spain to distinguish companies that make innovation their main business growth strategy, is endowed with 30,000 euros and has been granted to INMUNOTEK in the category of "Small and Medium-Sized Enterprise".
More info

INMUNOTEK awarded as "Best SME of the Year"

Inmunotek Pyme del año 2019November 2019

INMUNOTEK has been awarded as the Best SME of the Year 2019 by CEPYME (Spanish Confederation of Small and Medium-Sized Enterprises). This award recognizes Business Excellence under the criteria of business activity, innovation, internationalization and job creation. The award ceremony was chaired by the Spanish Minister of Economy and Business, Nadia Calviño, the President of CEPYME, Gerardo Cuerva and the CEO of Santander Bank, Rami Aboukhair, as sponsor of the award.
More info

UROMUNE in BMC Infectious Diseases

CistitisOctober 2019

A recent publication in BMC Infectious Diseases indicates that UROMUNE is effective against recurrent uncomplicated urological infections. The study, carried out on a total of 784 patients in the hospitals of Mataró and Moisés Broggi (Barcelona) between 2011-2017, concludes that treatment with UROMUNE was highly effective in reducing the number of infectious episodes at 3 and 6 months of follow-up . UROMUNE is a polybacterial mucosal vaccine developed by INMUNOTEK that is administered by sublingual spray.
More info

Alum impairs the effect of mannan-allergoid conjugates

October 2019

The effect of aluminum hydroxide on the tolerogenic properties of dendritic cells induced by allergoids coupled to mannan has been published in Allergy with the title "Alum impairs tolerogenic properties induced by allergoid-mannan conjugates inhibiting mTOR and metabolic reprogramming in human DCs". The study has been carried out at the School of Chemistry of the Complutense University of Madrid with the collaboration of INMUNOTEK.
More info

Trained Immunity-based Vaccines in El Escorial Summer Courses

Cursos verano El EscorialJuly 2019

Within the Summer Courses of El Escorial organized by the Complutense University of Madrid, the one entitled "Trained immunity-based vaccines: the innate immune memory working towards  antiinfectious immunotherapy" was held in Madrid during 11-12th of July under the direction of Dr. Silvia Sánchez Ramón (Immunology, San Carlos Clinical Hospital, Madrid) and Dr. Laura Conejero Hall (INMUNOTEK), Scientific Secretariat. The course, sponsored by INMUNOTEK, has combined basic aspects of the mechanisms of action of trained immunity, with the clinical outcome in recurrent respiratory and urinary tract infections.
More info

Effects of MV130 on oral epithelial cells

MV130 (Bactek)July 2019

Frontiers in Immunology publishes the article "Human Oral Epithelial Cells Impair Bacteria-Mediated Maturation of Dendritic Cells and Render T Cells Unresponsive to Stimulation". This research reveals the effect of MV130 on oral epithelial cells and the immunomodulation exerted by these cells on dendritic cells and T lymphocytes. The research, carried out in the School of Medicine of the Complutense University of Madrid, has been achieved with the collaboration of INMUNOTEK.
More info

The olive tree protagonist in the "Eliseo Subiza" Botanical Day

Jornada Eliseo Subiza_olivoMay 2019

The XXII Botanical Identification Seminar Day "Eliseo Subiza" was dedicated to the olive tree and took place in Toledo. This initiative of the Hospital Virgen del Valle (Toledo) has the collaboration of INMUNOTEK and is aimed to perform a botanical training of young allergists in main local allergenic plants. Through field trips with botanical experts and aerobiological lectures, each year is dedicated to special plant. The olive tree is a tree of great allergological interest as a cause of pollinosis in Spain since its pollen is very allergenic and affects a large number of patients.
More info